US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10 | Business Information & News | Westlaw

US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10 | Business Information & News | Westlaw

View on Westlaw or start a FREE TRIAL today, US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10, Business Information & News
5/7/24 REUTERS 14:12:11
REUTERS
Copyright (c) 2024 Thomson Reuters
May 7, 2024
US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10
Shinjini Ganguli
Christy Santhosh; Bengaluru
Pooja Desai
(Reuters) -Eli Lilly said on Tuesday a panel of independent U.S. FDA advisers will discuss its experimental Alzheimer's disease drug, donanemab, on June 10.
Donanemab has faced two separate regulatory delays in the United States, while a similar...
---- Index References ----
Industry: (Alzheimer's Disease & Dementia (1AL59); Geriatrics (1GE28); Healthcare (1HE06); Healthcare Practice Specialties (1HE49); Neurology (1NE95))
Language: EN
Other Indexing: (US FDA) (Eli Lilly)
Keywords: health
Word Count: 260
End of Document© 2024 Thomson Reuters. No claim to original U.S. Government Works.